<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324336</url>
  </required_header>
  <id_info>
    <org_study_id>6-MP pharmacokinetic 1</org_study_id>
    <nct_id>NCT01324336</nct_id>
  </id_info>
  <brief_title>Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets</brief_title>
  <official_title>Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Midwest Cancer Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Experimental Therapeutics in Pediatric Oncology Program at The Children's Mercy Hospitals and Clinics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics of a routinely used compounded
      liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in patients
      who are receiving treatment with 6-MP as part of their clinical treatment for acute
      lymphoblastic leukemia (ALL).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of 6-MP</measure>
    <time_frame>8 hours post administration</time_frame>
    <description>To compare the pharmacokinetics of a routinely used compounded liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in patients who are receiving treatment with 6-MP as part of their clinical treatment for acute lymphoblastic leukemia (ALL).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>4-17 years, receiving 6-MP</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-Mercaptopurine</intervention_name>
    <description>75 mg/m2/dose/day</description>
    <arm_group_label>4-17 years, receiving 6-MP</arm_group_label>
    <other_name>6-MP</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients ages 4-17 years of age who are receiving maintenance chemotherapy treatment for
        ALL with 6-MP will be included
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ages 4-17 years of age who are receiving maintenance chemotherapy treatment
             for ALL with 6-MP will be included.

        Exclusion Criteria:

          -  Inability to have blood drawn for the screening lab tests

          -  Received methotrexate or folate supplement within the last 24 hours

          -  Pregnant or lactating females

          -  Inability to swallow a pill

          -  Hemoglobin less or equal to 8 gm/dl

          -  Presence of significant co-morbid illness that makes child ineligible as deemed by the
             investigator

          -  Weight &lt; or = 16 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen A Neville, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Children's Mercy Hospitals and Clinics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara J Soliman, BSN</last_name>
    <phone>816-855-1977</phone>
    <email>sjsoliman@cmh.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Venneman, RN, MSN, MBA-HCM</last_name>
    <phone>816-234-3054</phone>
    <email>mvenneman@cmh.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Venneman</last_name>
      <phone>816-234-3059</phone>
      <email>mvenneman@cmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen A Neville, MD;MS</last_name>
      <phone>816-234-3059</phone>
      <email>kaneville@cmh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen A Neville, MD:MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Mercy Hospital Kansas City</investigator_affiliation>
    <investigator_full_name>Kathleen A Neville</investigator_full_name>
    <investigator_title>MD, MS</investigator_title>
  </responsible_party>
  <keyword>ALL</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>6-Mercaptopurine</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-Mercaptopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

